Kastelein, J. J. et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr. Med. Res. Opin. 23, 885-894
OBJECTIVE: The RADIANCE studies were designed to assess the effects of torcetrapib/atorvastatin (T/A) compared with atorvastatin alone on slowing atherosclerotic progression in patients with heterozygous familial hypercholesterolemia (RADIANCE 1) or mixed hyperlipidemia (RADIANCE 2), as measured by change in carotid intima-media thickness (CIMT). RESEARCH DESIGN AND METHODS: RADIANCE 1 and 2 were randomized, double-blind, controlled trials with a duration of 2 years. In both studies, eligible subjects began treatment with atorvastatin during a run-in period and were titrated to target LDL-C levels defined by NCEP ATP III guidelines. Subjects then proceeded to a double-blind randomized treatment period where they received one of two regimens: (i) fixed combination T/A (torcetrapib dose, 60 mg), or (ii) atorvastatin alone. In both regimens, the dose of atorvastatin was established during the run-in period (20-80 mg, RADIANCE 1; 10-80 mg RADIANCE 2). B-mode ultrasonography was performed in duplicate at baseline and at end of study, and every 6 months in between. MAIN OUTCOME MEASURES: The primary efficacy measure in both studies was the annualized rate of change in maximum CIMT of 12 pre-defined carotid segments. Further outcome measures included lipid and safety assessments. Current status: The number of subjects randomized was 904 in RADIANCE 1 and 752 in RADIANCE 2. Results are anticipated in 2007.
More support for high-dose atorvastatin in coronary artery diseaseLAROSA JC, GRUNDY SM, WATERS DD et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med (2005) 352:1425-1435  and YONEMURA A, MOMIYAMA Y, FAYAD ZA et al: Effect of lipid-lowering with atorvastatin on atherosclerotic aortic plaques detected by non-invasive magnetic resonance imaging. J. Am. Coll. Cardiol (2005) 45:733-742 .
Peginterferon is here to stay 1 1 Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon Alfa-2a in Patients With Chronic Hepatitis C N Engl J Med 2000;343:1666–72 2 2 Heathcote EJ, Shiffman ML, Cooksley WGE, et al.: Peginterferon Alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis N Engl J Med 2000;343:1673–80
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer: Robert NJ, Diéras V, Glaspy J, et al (Virginia Cancer Specialists, Fairfax; Univ of California, Los Angeles; Genentech, South San Francisco, CA; et al) J Clin Oncol 29:1252-1260, 2011§